Is Meropenemum [INN-Latin] Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Meropenemum [INN-Latin]? Is Meropenemum [INN-Latin] safe for nursing mother and child? Does Meropenemum [INN-Latin] extracts into breast milk? Does Meropenemum [INN-Latin] has any long term or short term side effects on infants? Can Meropenemum [INN-Latin] influence milk supply or can Meropenemum [INN-Latin] decrease milk supply in lactating mothers?

Antibacterial carbapenem beta-lactam with indications similar to imipenem.Intravenous administration every 8 hours. It is excreted in breast milk in a clinically insignificant amount (Sauberan 2012) and no problems have been observed in infants whose mothers took it (Festini 2004). Authorized pediatric use in infants and newborns. It is considered by experts to be compatible with breastfeeding (Rowe 2013). The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora (Benyamini 2005, Ito 1993, Kafetzis 1981).

Although no information is available on the use of Meropenemum [INN-Latin] during breastfeeding, milk levels appear to be low and beta-lactams are generally not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with beta-lactams, but these effects have not been adequately evaluated. Vaborbactam, which is available in the combination product Vabomere, has not been studied in nursing mothers, but the combination is expected to have similar concerns as with Meropenemum [INN-Latin] alone.

A mother received Meropenemum [INN-Latin] 1 gram IV every 8 hours for 7 days while exclusively breastfeeding her newborn. When questioned later, she stated that her infant had no oral thrush, watery diarrhea, or diaper dermatitis that required antifungal therapy during the month following her Meropenemum [INN-Latin] therapy.[1] An infant was breastfed (extent not stated) until the 4th month postpartum. At 2 months of age, his mother was given a 2-week course of tobramycin and Meropenemum [INN-Latin] (dosage not specified) for a cystic fibrosis exacerbation. The infant displayed no change in stool pattern during the maternal treatment and had normal renal function at 6 months of age.[2]